Nothing Special   »   [go: up one dir, main page]

AR090557A1 - DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 - Google Patents

DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2

Info

Publication number
AR090557A1
AR090557A1 ARP130101043A AR090557A1 AR 090557 A1 AR090557 A1 AR 090557A1 AR P130101043 A ARP130101043 A AR P130101043A AR 090557 A1 AR090557 A1 AR 090557A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
6alkyl
hydroxyalkyl
alkoxy
Prior art date
Application number
Other languages
English (en)
Inventor
Linnanen Tero
Koskelainen Tuula
Minkkil Anna
Mkel Mikko
Pohjakallio Antti
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR090557A1 publication Critical patent/AR090557A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), caracterizado porque X es O ó S; R¹ es hidroxi, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, ciano, alcoxi C₁₋₆alquilo C₁₋₆, alcoxi C₁₋₆alcoxi C₁₋₆alquilo C₁₋₆, hidroxialcoxi C₁₋₆, hidroxialcoxi C₁₋₆alquilo C₁₋₆, hidroxialquenilo C₂₋₆, alqueniloxi C₂₋₆alquenilo C₂₋₆, haloalcoxi C₁₋₆alquilo C₁₋₆, haloalcoxi C₁₋₆-haloalquilo C₁₋₆, alcoxi C₁₋₆-haloalcoxi C₁₋₆, carboxi, alquil C₁₋₆-(C=O)-, alcoxi C₁₋₆-(C=O)-, alquil C₁₋₆-(C=O)-O-, haloalquil C₁₋₆-(C=O)-, haloalcoxi C₁₋₆-(C=O)-, (R⁶)₂N-, (R⁶)₂N-alquilo C₁₋₆, (R⁶)₂N-(C=O)-, R⁶-(C=O)-N(R⁶)-(C=O)-, R⁶-(O=S=O)-N(R⁶)-(C=O)-, R⁶-(C=O)-N(R⁶)-(O=S=O)-, R⁶-(O=S=O)-N(R⁶)-(O=S=O)-, (R⁶)₂N-N-, (R⁶)N=N-, (R⁶)₂N-O-, (R⁶)O-N(R⁶)-, alquil C₁₋₆-S-, alquenil C₂₋₆-S-alquenilo C₂₋₆, hidroxialquil C₁₋₆-S-, hidroxialquil C₁₋₆-S-alquilo C₁₋₆, alcoxi C₁₋₆alquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-, haloalquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-haloalquilo C₁₋₆, R⁶-(O=S)-, (R⁶)₂N-(O=S)-, R⁶-(O=S=O)-, (R⁶)₂N-(O=S=O)-, fenilo, fenil-O-, heteroarilo, heteroaril-O-, fenil-N(R⁶)-, heteroaril-N(R⁶)-, o heteroarilalquilo C₁₋₆; R² es H, hidroxi, oxo, fluoro, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, ciano, alcoxi C₁₋₆alquilo C₁₋₆, alcoxi C₁₋₆alcoxi C₁₋₆alquilo C₁₋₆, hidroxialcoxi C₁₋₆, hidroxialcoxi C₁₋₆alquilo C₁₋₆, hidroxialquenilo C₂₋₆, alqueniloxi C₂₋₆alquenilo C₂₋₆, haloalcoxi C₁₋₆alquilo C₁₋₆, haloalcoxi C₁₋₆-haloalquilo C₁₋₆, alcoxi C₁₋₆-haloalcoxi C₁₋₆, carboxi, alquil C₁₋₆-(C=O)-, -alcoxi C₁₋₆-(C=O)-, alquil C₁₋₆-(C=O)-O-, haloalquil C₁₋₆-(C=O)-, haloalcoxi C₁₋₆-(C=O)-, (R⁶)₂N-, (R⁶)₂N-alquilo C₁₋₆, (R⁶)₂N-(C=O)-, R⁶-(C=O)-N(R⁶)-(C=O)-, R⁶-(O=S=O)-N(R⁶)-(C=O)-, R⁶-(C=O)-N(R⁶)-(O=S=O)-, R⁶-(O=S=O)-N(R⁶)-(O=S=O)-, (R⁶)₂N-N-, (R⁶)N=N-, (R⁶)₂N-O-, (R⁶)O=N-, alquil C₁₋₆-S-, alquenil C₂₋₆-S-alquenilo C₂₋₆, hidroxialquil C₁₋₆-S-, hidroxialquil C₁₋₆-S-alquilo C₁₋₆, alcoxi C₁₋₆alquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-, haloalquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-haloalquilo C₁₋₆, R⁶-(O=S)-, (R⁶)₂N-(O=S)-, R⁶-(O=S=O)-, (R⁶)₂N-(O=S=O)-, fenilo, fenil-O-, heteroarilo, heteroaril-O-, fenil-N(R⁶)-, heteroaril-N(R⁶)-, o heteroarilalquilo C₁₋₆; R³ es H, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, o cicloalquilo C₃₋₆; R⁴ es H, hidroxi, halógeno, alquilo C₁₋₂, o haloalquilo C₁₋₂; R⁵ es H, hidroxi, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₂, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, fenilo, o heteroarilo; y R⁶ es, independientemente en cada ocurrencia, H, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, haloalquilo C₁₋₆ o R⁶ y R⁶ forman, junto con los átomos a los cuales ellos se enlazan, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquil C₁₋₆-; o R¹ y R² forman, junto con los átomos de carbono en el anillo a los cuales ellos están enlazados, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquilo C₁₋₆; o R² y R³ forman, junto con los átomos de carbono en el anillo a los cuales ellos están enlazados, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquilo C₁₋₆; o una sal o éster del mismo aceptable desde el punto de vista farmacéutico.
ARP130101043 2012-04-02 2013-03-27 DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 AR090557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261619109P 2012-04-02 2012-04-02

Publications (1)

Publication Number Publication Date
AR090557A1 true AR090557A1 (es) 2014-11-19

Family

ID=48224812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101043 AR090557A1 (es) 2012-04-02 2013-03-27 DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2

Country Status (26)

Country Link
US (1) US9249127B2 (es)
EP (1) EP2834233B1 (es)
JP (1) JP6427096B2 (es)
KR (1) KR102104228B1 (es)
CN (1) CN104220437B (es)
AR (1) AR090557A1 (es)
AU (1) AU2013244859B2 (es)
BR (1) BR112014023957B1 (es)
CA (1) CA2868611C (es)
DK (1) DK2834233T3 (es)
ES (1) ES2674945T3 (es)
FR (1) FR22C1005I2 (es)
HK (1) HK1205115A1 (es)
HR (1) HRP20181203T1 (es)
HU (2) HUE039290T2 (es)
IL (1) IL234663B (es)
LT (2) LT2834233T (es)
MX (1) MX358429B (es)
NL (1) NL301160I2 (es)
NO (1) NO2022002I1 (es)
PL (1) PL2834233T3 (es)
PT (1) PT2834233T (es)
RU (1) RU2642065C2 (es)
SI (1) SI2834233T1 (es)
TW (1) TWI620746B (es)
WO (1) WO2013150173A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015152196A1 (ja) * 2014-03-31 2017-04-13 東レ株式会社 イミダゾリン誘導体及びその医薬用途
KR102601972B1 (ko) * 2015-02-11 2023-11-13 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체
CN105646306B (zh) * 2015-12-11 2020-06-30 广东莱佛士制药技术有限公司 一种4-甲硫基苯乙酸的制备方法
HUE059849T2 (hu) * 2017-12-01 2023-01-28 Orion Corp Eljárás 2-(5-metoxi-izokromán-1-il)-4,5-dihidro-1H-imidazol és annak hidrogénszulfát-sója elõállítására
CN110272407B (zh) * 2019-07-22 2021-02-05 河北省农林科学院经济作物研究所 一种用于降血压的天然异色满酮类化合物
WO2022195174A1 (en) 2021-03-19 2022-09-22 Orion Corporation Tasipimidine formulations and use thereof
CN118632846A (zh) 2022-01-24 2024-09-10 奥赖恩公司 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式
WO2023148431A1 (en) 2022-02-04 2023-08-10 Orion Corporation Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
WO2024069050A1 (en) 2022-09-28 2024-04-04 Orion Corporation Tasipimidine and cyp2d6 inhibitor combination treatment
CN117343036A (zh) * 2023-03-20 2024-01-05 江苏联环药业股份有限公司 异苯并二氢吡喃类化合物及其药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1247008B (de) * 1965-10-05 1967-08-10 Huels Chemische Werke Ag Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen
US3438995A (en) * 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
EP0166937B1 (en) * 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
JP2009524618A (ja) 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置における2−イミダゾールの使用
ATE458732T1 (de) 2006-01-27 2010-03-15 Hoffmann La Roche Verwendung von 4-imidazol-derivaten für zns- erkrankungen
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Also Published As

Publication number Publication date
FR22C1005I1 (fr) 2022-03-11
ES2674945T3 (es) 2018-07-05
LTPA2022001I1 (es) 2022-02-25
KR102104228B1 (ko) 2020-04-27
HK1205115A1 (en) 2015-12-11
PL2834233T3 (pl) 2018-09-28
CA2868611C (en) 2020-07-21
HUE039290T2 (hu) 2018-12-28
CA2868611A1 (en) 2013-10-10
NO2022002I1 (no) 2022-01-27
RU2014144284A (ru) 2016-05-27
AU2013244859B2 (en) 2017-06-22
MX2014011851A (es) 2014-11-21
TWI620746B (zh) 2018-04-11
DK2834233T3 (en) 2018-06-18
BR112014023957A2 (pt) 2017-06-20
RU2642065C2 (ru) 2018-01-24
CN104220437A (zh) 2014-12-17
BR112014023957B1 (pt) 2022-03-29
IL234663B (en) 2019-07-31
FR22C1005I2 (fr) 2024-10-25
PT2834233T (pt) 2018-07-17
WO2013150173A1 (en) 2013-10-10
HRP20181203T1 (hr) 2018-10-05
SI2834233T1 (en) 2018-08-31
TW201400478A (zh) 2014-01-01
US20150065550A1 (en) 2015-03-05
HUS2200005I1 (hu) 2016-04-28
BR112014023957A8 (pt) 2021-06-15
IL234663A0 (en) 2014-11-30
LT2834233T (lt) 2018-06-11
US9249127B2 (en) 2016-02-02
JP6427096B2 (ja) 2018-11-21
JP2015512438A (ja) 2015-04-27
MX358429B (es) 2018-08-20
EP2834233A1 (en) 2015-02-11
NL301160I2 (nl) 2022-04-06
AU2013244859A1 (en) 2014-10-02
EP2834233B1 (en) 2018-04-25
KR20140138826A (ko) 2014-12-04
CN104220437B (zh) 2017-11-10

Similar Documents

Publication Publication Date Title
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR097866A1 (es) Derivados de 4-azaindol
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
AR094300A1 (es) Derivados de quinolonas
RS54730B1 (sr) Inhibitori beta sekretaze
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR093937A1 (es) Compuestos quimicos
AR096153A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR090086A1 (es) COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b
AR100724A1 (es) Derivados de quinolina y su uso en enfermedades neurodegenerativas
AR089814A1 (es) Compuestos que modulan la actividad de los proteasomas
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
AR098965A1 (es) Derivados de sulfonamidas tricíclicas
AR093128A1 (es) Inhibidores de la syk

Legal Events

Date Code Title Description
FG Grant, registration